ES2B-C001, licensed to ExpreS2ion Biotechnologies, recently reported positive immunogenicity results from the first 12 of 13 currently recruited patients in the on-going Phase I clinical study, including all 5 patient to have completed the full five-dose regimen. Showing a 16-fold median improvement over baseline. This demonstrates Proof-of-Mechanism for AdaptVac's cVLP platform to consistently break tolerance against a self-antigen in humans. Expansion of the highest dose cohort with three additional patients has been approved by the DSMB, with study read-out expected by end-2026.
Follow this link to partner website for details on the HER2 program.
ES2B-C001
HER2+ Cancer
vaccine
VICI-Disease
consortium
Nipah virus
The VICI-DISEASE consortium’s objective is to develop a Nipah virus vaccine. Nipah virus causes high-mortality disease with no vaccines or treatments available.
The VICI-Disease consortium consists of AdaptVac, ExpreS2ion, Friedrich-Loeffler-Institut, the Radboud university medical center, Leipzig University and University of Copenhagen. Furthermore, PSG Institute of Medical Sciences and Research and Centre de Recherches Médicales de Lambaréné are associated participants in this grant-sponsored development project.
panFilovaxRR
Consortium
Orthoebola and
Orthomarburg viruses
The panFiloVaxRR consortium’s main objective is to develop a broadly protective filovirus vaccine candidate and perform a clinical proof-of-concept study, to enable stocks of vaccine candidates ready for clinical validation in large-scale efficacy trials in case of pandemic outbreaks.
The panFiloVaxRR consortium consists of AdaptVac, Friedrich-Loeffler-Institut, the Radboud university medical center, Leipzig University and University of Copenhagen, Centre de Recherches Médicales de Lambaréné and National Microbiology Laboratory, Public Health Agency of Canada. Including an out-sourced partner: Dyadic, USA .
ABNCoV2 met its primary endpoint in Phase 3, demonstrating non-inferiority to the Comirnaty® mRNA-vaccine, without the use of adjuvant. Additionally, safety data from 4,205 individuals followed up for 6 months post vaccination showed ABNCoV2 to be well-tolerated with no serious adverse events being reported.
ABNCoV2
COVID-19 vaccine
